title: Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.
abstract: HIV Prevention Trials Network 052 demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed to determine the genetic linkage status of partner infections. Forty-six infections were classified as linked, indicating that the index was the likely source of the partner's infection. Lack of viral suppression and higher index viral load were associated with linked infection. Eight linked infections were diagnosed after the index started ART: 4 near the time of ART initiation and 4 after ART failure. Linked infections were not observed when the index participant was stably suppressed on ART.
authors.affiliation: *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Laboratory of Immunoregulation, NIAID, NIH, Baltimore, MD; ‡Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC; §Vaccine and Infectious Disease Science Division, Fred Hutchinson Cancer Research Institute, Seattle, WA; ‖Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; ¶Genomics Unit, Research Technologies Section, Rocky Mountain Laboratories, DIR, NIAID, NIH, Hamilton, MT; #Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; **Science Facilitation Department, FHI360, Washington, DC; ††Science Facilitation Department, FHI360, Durham, NC; ‡‡College of Medicine-Johns Hopkins Project, Blantyre, Malawi; §§UNC Project, Lilongwe, Malawi; ‖‖Department of Medicine, University of Zimbabwe, Harare, Zimbabwe; ¶¶HIV Research Branch, Center for Global Health, Kenya Medical Research Institute (KEMRI)-Centers for Disease Control (CDC), Kisumu, Kenya; ##BHHRL & Clinical Trials Unit, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; ***Soweto HPTN CRS, Chris Hani Baragwanath Hospital, Soweto, South Africa; †††YRGCARE Medical Centre, Chennai, India; ‡‡‡Center for AIDS and STDs, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; §§§Hospital Nossa Senhora da Conceição, Serviço de Infectologia, Porto Alegre, Brazil; ‖‖‖Hospital Geral de Nova Iguaçu and Laboratorio de AIDS e Imunologia Molecular (IOC/Fiocruz), Rio de Janeiro, Brazil; ¶¶¶Instituto Nacional de Infectologia Evandro Chagas-INI-Fiocruz, Rio de Janeiro, Brazil; ###Fenway Health and Infectious Disease Division, The Fenway Institute, Boston, MA; ****Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA; ††††Vaccine and Infectious Disease Division and Public Health Science Division, Fred Hutchinson Cancer Research Institute, Seattle, WA; ‡‡‡‡Department of Biostatistics, University of Washington, Seattle, WA; and §§§§Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Susan H
authors.initials: SH
authors.lastname: Eshleman
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Hudelson
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Redd
authors.forename: Ronald
authors.initials: R
authors.lastname: Swanstrom
authors.forename: San-San
authors.initials: SS
authors.lastname: Ou
authors.forename: Xinyi Cindy
authors.initials: XC
authors.lastname: Zhang
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Ping
authors.forename: Estelle
authors.initials: E
authors.lastname: Piwowar-Manning
authors.forename: Stephen F
authors.initials: SF
authors.lastname: Porcella
authors.forename: Matthew F
authors.initials: MF
authors.lastname: Sievers
authors.forename: Craig A
authors.initials: CA
authors.lastname: Martens
authors.forename: Daniel
authors.initials: D
authors.lastname: Bruno
authors.forename: Elena
authors.initials: E
authors.lastname: Dukhovlinova
authors.forename: Marybeth
authors.initials: M
authors.lastname: McCauley
authors.forename: Theresa
authors.initials: T
authors.lastname: Gamble
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Fogel
authors.forename: Devin
authors.initials: D
authors.lastname: Sabin
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Quinn
authors.forename: Laurence
authors.initials: L
authors.lastname: Gunde
authors.forename: Madalitso
authors.initials: M
authors.lastname: Maliwichi
authors.forename: Nehemiah
authors.initials: N
authors.lastname: Nhando
authors.forename: Victor
authors.initials: V
authors.lastname: Akelo
authors.forename: Sikhulile
authors.initials: S
authors.lastname: Moyo
authors.forename: Ravindre
authors.initials: R
authors.lastname: Panchia
authors.forename: Nagalingeswaran
authors.initials: N
authors.lastname: Kumarasamy
authors.forename: Nuntisa
authors.initials: N
authors.lastname: Chotirosniramit
authors.forename: Marineide Gonçalves de
authors.initials: MG
authors.lastname: Melo
authors.forename: Jose
authors.initials: J
authors.lastname: Pilotto
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Kenneth
authors.initials: K
authors.lastname: Mayer
authors.forename: Ying Q
authors.initials: YQ
authors.lastname: Chen
authors.forename: James P
authors.initials: JP
authors.lastname: Hughes
authors.forename: Myron S
authors.initials: MS
authors.lastname: Cohen
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018890:Chemoprevention / Q000379:methods*; D015331:Cohort Studies; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents